---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-23-006005"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2023-10-24T23:59:59+00:00"
generated_at: "2026-06-09T13:59:39.998527+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma to spin off Citius Oncology via merger with SPAC TenX Keane

## Summary
- Citius Pharma (CTXR) entered a merger agreement for its subsidiary Citius Oncology to combine with TenX Keane Acquisition.
- Upon close, TenX will domesticate to Delaware and change name to 'Citius Oncology, Inc.'; expected close first half 2024.
- SpinCo shares convert to New Citius Oncology shares using Base Exchange Ratio of 67.5M / outstanding SpinCo shares.
- Termination rights include FDA CRL for Lymphir; $5M termination fee payable by Citius Pharma under certain conditions.
- Sponsor 10XYZ Holdings supports transaction; post-close registration rights and shared services agreements planned.

## SEC filing metadata
- accession: 0001013762-23-006005
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2023-10-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000101376223006005/0001013762-23-006005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000101376223006005/ea186984-8k425_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-23-006005
- JSON: https://secwatch.observer/filing/0001013762-23-006005.json
- Plain text: https://secwatch.observer/filing/0001013762-23-006005.txt

## Key facts
- Material Agreements
  Citius Pharmaceuticals, Inc. entered into Merger Agreement with TenX Keane Acquisition (effective 2023-10-23).
  - Action: entry
  - Agreement: merger
  - Counterparty: TenX Keane Acquisition
  - Effective: 2023-10-23
  source text: On October 23, 2023, Citius Pharmaceuticals, Inc. (“Citius Pharma”) and Citius Oncology, Inc. (“SpinCo”), a wholly owned subsidiary of Citius Pharma, entered into an agreement and plan of merger and reorganization (the “Merger Agreement”) with TenX Keane Acquisition, a Cayman Islands exempted company (“TenX”), and TenX Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of TenX (“Merger Sub”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000101376223006005/0001013762-23-006005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.